Medicine and Dentistry
Disease
100%
Non-Hodgkin Lymphoma
95%
Overall Survival
70%
Diffuse Large B-Cell Lymphoma
51%
Malignant Neoplasm
48%
Neoplasm
47%
Hodgkin's Lymphoma
47%
Clinical Trial
38%
Transplantation
38%
Peripheral T-Cell Lymphoma
38%
Oncology
34%
Drug Megadose
33%
Mantle Cell Lymphoma
30%
Progression Free Survival
29%
Multiple Myeloma
29%
Rituximab
26%
Lung Cancer
23%
Follicular Lymphoma
23%
Autologous Stem Cell Transplantation
23%
Bone Marrow Transplantation
22%
Breast Cancer
22%
Non Small Cell Lung Cancer
21%
T Cell
21%
Radiation Therapy
21%
Hematopoietic Stem Cell
20%
B Cell
19%
Cell Transplantation
18%
Autotransplantation
18%
Large-Cell Lymphoma
18%
High Dose Chemotherapy
18%
B-Cell Chronic Lymphocytic Leukemia
18%
Lenalidomide
16%
Cancer
16%
Hematopoietic Stem Cell Transplantation
16%
Acute Myeloid Leukemia
15%
Autologous Bone Marrow Transplantation
15%
Targeted Therapy
15%
Metastatic Carcinoma
15%
Small Cell Lung Cancer
15%
Prognostic Factor
15%
Autologous Hematopoietic Stem Cell Transplantation
15%
Cyclophosphamide
15%
Doxorubicin
14%
B-Cell Lymphoma
14%
Immunotherapy
12%
Surgery
12%
T-Cell Lymphoma
12%
Stem Cell
12%
Systemic Therapy
12%
Central Nervous System
12%
International Prognostic Index
12%
Vincristine
12%
Lymphocytic Lymphoma
11%
Multivariate Analysis
11%
Chemoradiotherapy
11%
Adverse Event
10%
Prednisone
10%
Stem Cell Transplant
10%
Myeloma
10%
Survival Rate
9%
Hematologic Malignancy
9%
Minimal Residual Disease
9%
NK T Cell Lymphoma
9%
Prostate Cancer
8%
Event Free Survival
8%
Pancreas Cancer
8%
Hazard Ratio
8%
Lymphoma
8%
Peripheral Stem Cell Transplantation
8%
Risk Stratification
8%
Failure Free Survival
8%
Burkitt's Lymphoma
8%
Diagnosis
8%
Anaplastic Large Cell Lymphoma
8%
Recurrent Disease
8%
Oncologist
7%
Tumor Cell
7%
Hemopoietic Growth Factor
7%
Colon Cancer
7%
Infection
7%
Supportive Care
7%
Glioblastoma
7%
Patient with Non-Hodgkins Lymphoma
7%
Allogeneic Hematopoietic Stem Cell Transplantation
7%
Chemotherapy Regimens
7%
Allogeneic Stem Cell Transplantation
7%
Classical Hodgkin Lymphoma
7%
Lymphoma Cell
7%
Pancreas Adenocarcinoma
7%
Adjuvant Therapy
7%
Disease Course
7%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
7%
Maintenance Therapy
7%
Myelodysplastic Syndrome
7%
Aggressive Lymphoma
7%
Gene Expression Profiling
6%
Adjuvant Chemotherapy
6%
Positron Emission Tomography
6%
Biopsy
6%
Retrospective Study
6%
Pharmacology, Toxicology and Pharmaceutical Science
Nonhodgkin Lymphoma
55%
Chemotherapy
54%
Disease
49%
Overall Survival
42%
Malignant Neoplasm
38%
Clinical Trial
29%
Neoplasm
28%
Progression Free Survival
24%
Multiple Myeloma
24%
Lung Cancer
22%
Hodgkin Disease
21%
Lenalidomide
19%
Diffuse Large B Cell Lymphoma
18%
Rituximab
18%
Remission
17%
Cyclophosphamide
16%
Doxorubicin
15%
High Dose Chemotherapy
15%
Peripheral T Cell Lymphoma
14%
Mantle Cell Lymphoma
14%
Breast Cancer
13%
Adverse Event
13%
Prednisone
12%
Non Small Cell Lung Cancer
12%
Farnesyl Trans Transferase
12%
Follicular Lymphoma
10%
Vincristine
10%
Large Cell Lymphoma
10%
Prostate Cancer
10%
Chemoradiation Therapy
9%
Bisphosphonic Acid Derivative
9%
Immunotherapy
9%
Small Cell Lung Cancer
9%
Epidermal Growth Factor Receptor
9%
Survival Rate
9%
Isoprenoid
9%
Pancreas Cancer
8%
Acute Myeloid Leukemia
8%
Etoposide
7%
Chronic Lymphatic Leukemia
7%
Biological Marker
7%
Pancreas Adenocarcinoma
6%
Myeloma
6%
Solid Malignant Neoplasm
6%
Myelodysplastic Syndrome
6%
Dexamethasone
6%
B Cell Lymphoma
6%
Thrombocytopenia
6%
Event Free Survival
6%
Monotherapy
6%
Gemcitabine
5%
Recurrent Disease
5%
Hemopoietic Growth Factor
5%
Triazole
5%
Bortezomib
5%
Placebo
5%
Combination Therapy
5%
Failure Free Survival
5%
Anthracycline
5%
Phase II Trials
5%
Cisplatin
5%
Cytokine
5%
Infection
5%
Monoclonal Antibody
5%
Granulocyte Colony Stimulating Factor
5%
Hematologic Malignancy
5%
Iodine-131
5%
Keyphrases
Non-Hodgkin Lymphoma
40%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
37%
Lymphoma
34%
Diffuse Large B-cell Lymphoma (DLBCL)
26%
NCCN Guidelines
24%
Overall Survival
23%
Chemotherapy
23%
Peripheral T-cell Lymphoma
21%
Oncology
18%
Relapsed or Refractory
17%
Mantle Cell Lymphoma
14%
Multiple Myeloma
14%
Hodgkin Disease
14%
Allogeneic Bone Marrow Transplantation
14%
Clinical Trials
13%
Bone Marrow Transplantation
13%
High-dose Chemotherapy
13%
High-dose Therapy
12%
Follicular Lymphoma
11%
Clinical Practice Guidelines
11%
Marrow Transplantation
11%
Progression-free Survival
11%
Transplantation
11%
Hodgkin Lymphoma
10%
Confidence Interval
9%
Complete Remission
9%
Autologous Transplantation
8%
Initial Treatment
8%
Older Patients
8%
Lenalidomide
8%
T Cells
8%
T-cell Lymphoma
7%
Rituximab
7%
Bone Marrow
7%
Acute Myeloid Leukemia
7%
Newly Diagnosed
7%
Nebraska
7%
Granulocyte Colony-stimulating Factor (G-CSF)
7%
Hematopoietic Stem Cell Transplantation
6%
Relapsed Lymphoma
6%
Breast Cancer
6%
Myeloma
6%
Treatment Options
6%
Hematopoietic Growth Factors
6%
Chronic Lymphocytic Leukemia
6%
Colon Cancer
6%
Small Cell Lung Cancer
6%
Large B-cell Lymphoma
6%
Non-small Cell Lung Cancer (NSCLC)
6%
Myelodysplastic Syndrome
5%
Doxorubicin
5%
Young Patients
5%
Systemic Therapy
5%
Combined Modality Therapy
5%
NCCN Clinical Practice Guidelines
5%
Pancreatic Cancer
5%
Early-stage Lung Cancer
5%
Lung Cancer
5%
Targeted Therapy
5%
Malignancy
5%
5-year Survival
5%
Cyclophosphamide
5%
Clinical Outcomes
5%
United States
5%
Tumor
5%
Multivariate Analysis
5%
Risk Stratification
5%
Chemotherapy Regimen
5%
International Prognostic Index
5%